To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
A receptor antagonist is a type of receptor ligand or drug that does not provoke a biological response itself upon binding to a receptor, but blocks or attenuates agonist-mediated responses. In pharmacology, antagonists have affinity but no efficacy for their cognate receptors and binding will disrupt the interaction and inhibit the function of an agonist or inverse agonist at receptors. Antagonists mediate their effects by binding to the active site or to allosteric sites on receptors or they may interact at unique binding sites not normally involved in the biological regulation of the receptor's activity. Antagonist activity may be reversible or irreversible depending on the longevity of the antagonist–receptor complex which in turn depends on the nature of antagonist receptor binding. The majority of drug antagonists achieve their potency by competing with endogenous ligands or substrates at structurally defined binding sites on receptors.
Additional recommended knowledge
Biochemical receptors are large molecules (usually proteins) that can be activated by a binding of a ligand (such as a hormone or drug). Receptors can be membrane-bound occurring on the cell membrane of cells or intracellular as for nuclear receptors. Binding occurs as a result of noncovalent interaction between the receptor and its ligand, at locations called the binding site on the receptor. A receptor may contain one or more binding sites for different ligands. Binding to the active or orthostatic site on the receptor regulates receptor activation directly. The activity of receptors can also be regulated by binding of a ligand to other sites on the receptor termed allosteric sites. Antagonists mediate their affects through receptor interactions by preventing agonist-induced responses. This may be accomplished by binding to the active site or at the allosteric site. In addition, antagonists may interact at unique binding sites not normally involved in the biological regulation of the receptor's activity to exert their affects.
The term antagonist was originally coined to describe different profiles of drug effects. The biochemical definition of a receptor antagonist was introduced by Ariens and Stephanson in the 1950s. The current accepted definition of receptor antagonist is based on the receptor occupancy model. It narrows the definition of antagonism to consider only those compounds with opposing activities at a single receptor. Agonists were thought to turn "on" a single cellular response by binding to the receptor, thus initiating a biochemical mechanism for change within a cell. Antagonists were thought to turn "off" that response by 'blocking' the receptor from the agonist. This definition also remains in use for physiological antagonists, substances which have opposing physiological actions, but act at different receptors. For example, histamine lowers arterial pressure through vasodilation at the histamine H1 receptor, while adrenaline raises arterial pressure through vasoconstriction mediated by β-adrenergic receptor activation.
Our understanding of the mechanism of drug induced receptor activation and receptor theory and the biochemical definition of a receptor antagonist continues to evolve. The two state model of receptor activation has given way to multistate models with intermediate conformational states. The discovery of functional selectivity and that ligand-specific receptor conformations occur and can affect interaction of receptors with different second messenger systems may mean that drugs can be designed to activate some of the downstream functions of a receptor but not others. The theory alters the view that efficacy at a receptor is receptor-independent property of a drug and that efficacy may actually depend on where that receptor is expressed.
Efficacy and potency
By definition, antagonists display no efficacy to activate the receptors they bind. Antagonists do not maintain the ability to activate a receptor. Once bound, however, antagonists inhibit the function of agonists, inverse agonists and partial agonists. In functional antagonist assays a dose-response curve measures the effect of the ability of a range of concentrations of antagonists to reverse the activity of an agonist. The potency of an antagonist is usually defined by its IC50 value. This can be calculated for a given antagonist by determining the concentration of antagonist needed to elicit half inhibition of the maximum biological response of an agonist. Elucidating an IC50 value is useful for comparing the potency of drugs with similar efficacies, however the dose-response curves produced by both drug antagonists must be similar. The lower the IC50, the greater the potency of the antagonist, the lower the concentration of drug that is required to inhibit the maximum biological response. Lower concentrations of drugs may be associated with fewer side effects.
The affinity of an antagonist for its binding site ki or ability to bind a receptor will determine the duration of inhibition of agonist activity. The affinity of an antagonists can be determined experimentally using Schild regression or for competitive antagonists in radioligand binding studies using the Cheng-Prusoff equation. Schild regression can be used to determine the nature of antagonism as beginning either competitive or non-competitive and ki determination is independent of the affinity, efficacy or concentration of the agonist used. However it is important that equilibrium has been reached. The effects of receptor desensitization on reaching equilibrium must also be taken into account. The affinity constant of antagonists exhibiting two or more effects such as competitive neuromuscular-blocking agents which also block ion channels as well as antagonising agonist binding cannot be analysed using schild regression  Schild regression involves comparing the change in the dose ratio, the ratio of the EC50 of an agonist alone compared to the EC50 in the presence of a competitive antagonist as determined on a dose response curve. Altering the amount of antagonist used in the assay can alter the dose ratio. In Schild regression a plot is made of the log(dose ratio-1) versus the log concentration of antagonist for a range of antagonist concentrations. The affinity or ki is where the line cuts the x-axis on the regression plot. Whereas with Schild regression antagonist concentration is varied in experiments used to derive ki values from the Cheng-Prusoff equation agonist concentrations are varied. Affinity for competitive agonists and antagonists is related by the Cheng-Prusoff factor used to calculate the Ki(affinity constant for an antagonist) from the shift in IC50 that occurs during competitive inhibition. The Cheng-Prusoff factor takes into account the effect of altering agonist concentration and agonist affinity for the recepor on inhibition produced by competitive antagonists.
Types of antagonists
Competitive antagonists reversibly bind to receptors at the same binding site the active site as the endogenous ligand or agonist, but without activating the receptor. Agonists and antagonists "compete" for the same binding site on the receptor. Once bound, an antagonist will block agonist binding. The level of activity of the receptor will be determined by the relative affinity of each molecule for the site and their relative concentrations. High concentrations of a competitive agonist will increase the proportion of receptors which the agonist occupies, higher concentrations of the antagonist will be required to obtain the same degree of binding-site occupancy. In functional assays using competitive antagonists a parallel rightward shifts of agonist dose–response curves with no alteration of the maximal response is observed. The interleukin-1 receptor antagonist, IL-1Ra is an example of a cometitive antagonist. The effects of a competitive antagonist may be overcome by increasing the concentration of agonist. Often (though not always) these antagonists possess a very similar chemical structure to that of the agonist.
Non-competitive antagonists are also known as allosteric antagonist. These antagonists bind to a distinctly separate binding site from the agonist, exerting their action to that receptor via the other binding site. Cyclothiazide has been shown to act as a reversible non-competitive antagonist of mGluR1 receptor. Thus they do not compete with agonists for binding. The bound antagonists may result in a decreased affinity of an agonist for that receptor, or alternatively may prevent conformational changes in the receptor required for receptor activation after the agonist binds. No amount of agonist can completely overcome the inhibition once it has been established. In functional assays of non-competitive antagonists depression of the maximal response of agonist dose-response curves and in some cases rightward shifts is produced. The rightward shift will occur as a result of a receptor reserve and inhibition of the agonist response will only occur when this reserve is depleated.
Uncompetivite antagonists differ from non-competitive antagonists in that they require receptor activation by an agonist before binding can occur to the separate allosteric binding site of the antagonist. This type of antagonism produces a kinetic profile in which "the same amount of antagonist blocks higher concentrations of agonist better than lower concentrations of agonist". Memantine, used in the treatment of Alzheimer's disease, is an uncompetitive antagonist of the NMDA receptor.
Partial agonists and inverse agonists
Partial agonists are defined as drugs which at a given receptor might differ in the amplitude of the functional response that they elicit after maximal receptor occupancy. Although they are agonists, partial agonist can act as a competitive antagonist if co-administered with a full agonist, as it competes with the full agonist for receptor occupancy and producing a net decrease in the receptor activation observed with the full agonist alone. Clinically, their usefulness is derived from their ability to enhance deficient systems while simultaneously blocking excessive activity. Exposing a receptor to a high level of the partial agonist will ensure that it has a constant, weak level of activity whether its normal agonist is present at high or low levels. In addition, it has been suggested that partial agonism prevents the adaptive regulatory mechanisms that frequently develop after repeated exposure to potent full agonists or antagonists. Buprenorphine a partial agonist of the μ-opioid receptor binding it with weak morphine-like activity and is used clinically as an analgesic in pain management and in reversing morphine addiction as an alternative to methodone in the treatment of drug addiction.
An inverse agonist can have effects similar to an antagonist, but causes a distinct set of downstream biological responses. Contitutively active receptors which exhibit intrinsic or basal activity can have inverse agonists, which not only block the effects of binding agonists like a classical antagonist, but inhibit the basal activity of the receptor. Drugs previously classified as antagonists are now beginning to be reclassified as inverse agonists because of the discovery of constitutive active receptors. Antihistamines, originally classified as antagonists of histamine H1 receptors have been reclassified as inverse agonists.
Many antagonists are considered reversible antagonists because they, like most agonists, will bind and unbind a receptor at rates determined by the receptor-ligand kinetics.
Irreversible antagonists covalently bind to the receptor target and generally cannot be removed; inactivating the receptor the duration of the antagonist effects is determined by the rate of receptor turnover, the rate of synthesis of new receptors. Phenoxybenzamine is an example of an irreversible alpha blocker—it permanently binds to α adrenergic receptors, preventing adrenaline and noradrenaline from binding. Inactivation of receptors normally results in a depression of the maximal response of agonist-dose response curves and right shift in the curve occurs where there is a receptor reserve similar to non-competitive antagonists. A washout step in the assay will usually distinguish between non-competitive and irreversible antagonist drugs as effects of non-competitive antagonists are reversible and activity of agonist will be restored.
Competitive irreversible antagonists like competitive antagonists also involves competition between agonist and antagonists of the receptor but stronger binding forces, usually involving covalent binding of the antagonist to the agonist binding site on the receptor, in which case there is a period before the covalent bond forms determined by receptor-ligand kinetics during which competing ligands can prevent the inhibition. Once binding of the antagonist occurs however even at high agonist concentrations the effect of the antagonist cannot be fully reversed. As for non-competitive antagonists and irreversible antagonists in functional assays with irreversible competitive antagonist drugs there may be a shift in the log concentration–effect curve to the right but generally both a decrease in slope and reduced maximum are obtained.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Receptor_antagonist". A list of authors is available in Wikipedia.|